VYNE Therapeutics (VYNE) announced the appointment of Subhashis Banerjee, M.D., as Senior Vice President, SVP, of Clinical Development, effective as of July 8, 2024. Dr. Banerjee is a trained immunologist and rheumatologist with over 25 years of drug development experience at large pharmaceutical companies, including with the development of therapies for psoriasis and arthritic conditions. Prior to joining VYNE, Dr. Banerjee served as Vice President & Disease Area Head, Rheumatology and Dermatology at Bristol Myers Squibb (BMY)
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VYNE:
- VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum
- VYNE Therapeutics announces dosing of first patients in Phase 1a trial of VYN202
- VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202
- VYNE Therapeutics announces dosing of first subject in Phase 2b trial of VYN201
- VYNE Therapeutics Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201
Questions or Comments about the article? Write to editor@tipranks.com